Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity

Limitations to successful gene therapy with adeno-associated virus (AAV) can comprise pre-existing neutralizing antibodies to the vector capsid that can block cellular entry, or inefficient transduction of target cells that can lead to sub-optimal expression of the therapeutic transgene. Recombinant...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Ther Methods Clin Dev
Auteurs principaux: Biswas, Moanaro, Marsic, Damien, Li, Ning, Zou, Chenhui, Gonzalez-Aseguinolaza, Gloria, Zolotukhin, Irene, Kumar, Sandeep R.P., Rana, Jyoti, Butterfield, John S.S., Kondratov, Oleksandr, de Jong, Ype P., Herzog, Roland W., Zolotukhin, Sergei
Format: Artigo
Langue:Inglês
Publié: American Society of Gene & Cell Therapy 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7591349/
https://ncbi.nlm.nih.gov/pubmed/33145371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2020.09.019
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires